Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003018 · ClinicalTrials.gov registry record · Phase 2
S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT00003018 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 54 participants.
The verdict
NCT00003018, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG dipyridamole
- DRUG mitomycin C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 1997-09 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003018
The ClinicalTrials.gov registry entry for NCT00003018 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which fluorouracil is the first listed.
NCT00003018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003018 about?
NCT00003018 is a clinical study titled "S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the ef...
What is the current status of trial NCT00003018?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 1997-09. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00003018?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), dipyridamole (DRUG), mitomycin C (DRUG).
Who is sponsoring clinical trial NCT00003018?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.